HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Karen Lutz Selected Research

pramlintide (Symlin)

5/2013Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy.
9/2009Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study.
9/2009Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes.
11/2007Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin.
4/2007Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight.
10/2006A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes.
11/2003Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Karen Lutz Research Topics

Disease

4Type 1 Diabetes Mellitus (Autoimmune Diabetes)
05/2013 - 11/2003
3Nausea
05/2013 - 10/2006
3Type 2 Diabetes Mellitus (MODY)
09/2009 - 04/2007
3Hypoglycemia (Reactive Hypoglycemia)
09/2009 - 10/2006
2Body Weight (Weight, Body)
05/2013 - 11/2007
2Weight Gain
09/2009 - 11/2007
2Weight Loss (Weight Reduction)
11/2007 - 04/2007
1Insulin Resistance
11/2011
1Diabetes Mellitus
11/2011
1Lipodystrophy
11/2011
1Hypertriglyceridemia
11/2011
1Congenital Generalized Lipodystrophy (Berardinelli-Seip Congenital Lipodystrophy)
11/2011

Drug/Important Bio-Agent (IBA)

7pramlintide (Symlin)FDA Link
05/2013 - 11/2003
6Insulin (Novolin)FDA Link
05/2013 - 11/2003
4Glucose (Dextrose)FDA LinkGeneric
09/2009 - 11/2003
2Short-Acting InsulinIBA
09/2009 - 11/2003
1Glycated Hemoglobin (Glycosylated Hemoglobin)IBA
05/2013
1Blood Glucose (Blood Sugar)IBA
05/2013
1metreleptinIBA
11/2011
1LipidsIBA
11/2011
1Triglycerides (Triacylglycerol)IBA
11/2011
1LeptinIBA
11/2011
1Glucagon (Glukagon)FDA Link
09/2009
1Islet Amyloid PolypeptideIBA
11/2003
1Insulin Lispro (Humalog)FDA Link
11/2003

Therapy/Procedure

3Therapeutics
05/2013 - 10/2006
3Glycemic Control
05/2013 - 04/2007
1Subcutaneous Injections
11/2011